Finding the right CMC advisor can become difficult when development timelines are tight, technical information is distributed across manufacturers, laboratories and internal teams, and decisions made today can affect the quality dossier later in the product lifecycle. Companies may have strong scientific expertise in-house, but still lack the capacity to coordinate CMC inputs, prepare submission-ready documentation and connect technical decisions with wider regulatory affairs requirements.

The problem becomes more visible when external support remains too far from the day-to-day programme. Questions move between several contacts, technical recommendations are delivered without ownership of the follow-up work, and internal teams are left to convert advice into documents, actions and authority-ready responses. This can slow progress at the exact moment when the company needs clarity, continuity and fast access to experienced support.

For companies exploring alternatives to large pharma-affiliated cmc advisors, the priority should be a working model that combines specialist CMC knowledge with direct access and practical execution. The right CMC advisor should understand the product context, work with the people generating the technical information and help translate that information into regulatory deliverables that support the next milestone. For pharma and biotech teams that need specialist expertise without adding another layer of coordination, a more direct CMC advisory model can provide the access, continuity and practical support needed to keep the programme moving.

What should companies define before engaging a CMC advisor?

Before appointing a CMC advisor, companies should define the business and regulatory problem they want external support to solve. The need may be a specific CMC deliverable, additional capacity before a submission, coordination of data from several technical parties, support for an authority interaction or help bringing documentation to a level where it can move forward efficiently. Setting a clear scope keeps the engagement targeted and ensures a defined outcome.

The first step is to map what information already exists, what is still being generated and who owns each input. CMC content may depend on API and finished-product manufacturers, analytical laboratories, development specialists, quality teams and regulatory colleagues. This is also where experienced regulatory affairs consulting can add value: the advisor needs to understand not only the technical content, but also how that content will be used within a regulatory pathway and where inconsistencies could create additional work later.

Companies should also agree what “support” means in practice. Is the advisor expected to review and recommend, prepare or rewrite documentation, coordinate contributors, assess the impact of new data, support responses to questions or remain involved until a milestone is completed? Defining deliverables, interfaces and decision rights at the beginning creates a better basis for timelines and accountability. It also makes it easier to evaluate whether a potential CMC advisor offers the level of involvement the programme actually needs rather than simply listing a broad range of capabilities.

How can Billev Pharma East support you as your CMC advisor?

At Billev Pharma East, we combine regulatory expertise with hands-on execution. Our regulatory services include CMC writing for APIs and finished dosage forms, full dossier compilation, lifecycle management, regulatory submissions, project management and communication with regulatory authorities. This allows us to support the work that follows a CMC decision, not only the discussion around it. For clients, the practical benefit is a clearer route from technical information to a regulatory deliverable that can actually be used. This means clients can engage us for a defined CMC workstream without having to outsource the entire regulatory function. Where broader CMC consulting is required, the scope can expand around the programme while keeping responsibilities and ownership clear.

Our support can be tailored to the point at which your team needs additional capacity. We can work with existing technical information, help organise input from manufacturers and laboratories, prepare or revise CMC documentation and maintain continuity as the project progresses. Where several contributors are involved, we help keep the regulatory output aligned with the product, the development stage and the agreed submission objective. This can be especially useful when a company is considering broader regulatory outsourcing but wants to retain direct visibility and control over the CMC workstream.

Because our wider team works across regulatory affairs, quality, medical consultancy and lifecycle activities, we can also place CMC questions in the broader context when the project requires it. Instead of handing a client a list of observations and leaving implementation to the internal team, our aim is to stay close to the work, clarify what is needed next and help complete the agreed deliverables. For pharma and biotech companies looking for a practical CMC advisor, that combination of specialist input and execution is central to how we work.

What matters when looking beyond large pharma-affiliated CMC advisors?

For companies evaluating alternatives to large pharma-affiliated cmc advisors, the most useful comparison is not simply the size of the consultancy. It is how the advisory model will function once the work starts. Direct access matters because CMC questions often need clarification across development, manufacturing, analytical and regulatory functions. Companies should know who will perform the work, whether the same experts will remain involved and how quickly technical questions can reach the people who can resolve them.

Flexibility is equally important. A project may begin with one document and later expand into data coordination, a regulatory question, a manufacturing change or a broader submission activity. This is particularly relevant for growing biotech teams, where the need for biotech regulatory consulting may change quickly as development progresses. A useful CMC advisor should therefore be able to scale involvement around the programme rather than forcing every assignment into the same service model.

Companies should also compare the amount of practical ownership included in the engagement. Strategic advice is valuable, but it may not solve the resource problem if the internal team must still convert every recommendation into an action plan, revised dossier section or authority response. A more direct model should make responsibilities visible from the start: what the advisor will deliver, what information the client must provide and which decisions remain with the company. The goal is not to choose “large” or “small”; it is to choose the working model that gives the programme the right expertise, access and level of involvement.

What should a CMC advisor be able to deliver?

A CMC advisor should be able to translate technical and regulatory understanding into defined outputs. Depending on the product and development stage, this may include preparing or revising quality documentation, reviewing information received from manufacturers and laboratories, coordinating contributors, supporting responses to technical questions or assessing how new data affect the existing regulatory package. The value of the advisor is therefore measured not only by subject-matter knowledge, but by the quality and usability of the deliverables produced.

The advisor should also understand how quality information fits into the wider submission structure. CMC content does not sit in isolation: it needs to remain coherent across relevant CTD modules and, where electronic submission is required, the structure and maintenance of eCTD modules must support a consistent regulatory record. A manufacturing change, analytical update or new stability result can therefore affect several connected documents rather than one isolated section.

For some companies, the immediate requirement is narrower. A focused CMC assessment may be appropriate when the main objective is to evaluate the completeness or robustness of an existing package. When the need extends beyond assessment, the advisor may also be expected to prepare documents, coordinate implementation and remain involved through the next milestone. Keeping those needs distinct avoids overlap with the gap assessment, ensuring the CMC advisor stays focused on delivering the required work.

How should CMC support fit into regulatory strategy and lifecycle work?

CMC decisions should support the wider regulatory strategy rather than being managed as a separate technical stream. Development choices, manufacturing changes, analytical controls and stability commitments can all affect the timing and content of future submissions. A strong CMC advisor therefore needs to understand not only the immediate technical issue, but also what the decision means for the next regulatory step and for the product later in its lifecycle.

This becomes increasingly important once a product has an established submission history. New sequences, variations and supporting documents need to remain consistent with what has already been filed, therefore eCTD lifecycle management should be considered when planning how updated CMC information will be introduced over time. The practical focus should remain on maintaining a coherent regulatory record as approved information changes.

Companies should also consider how responsibilities continue after the immediate submission. Manufacturing information and registered details evolve, and the practical value of lifecycle management services is highest when changes are assessed early enough to understand their regulatory impact. The objective is continuity: technical decisions, regulatory documentation and submission history should continue to tell the same story as the product develops. This is where a CMC advisor who understands the wider lifecycle can reduce avoidable rework and support more controlled decision-making.

When is the right time to bring in a CMC advisor?

A CMC advisor can add the most value while there is still time to influence the next step. Companies do not need to wait until a submission is approaching or a technical issue has already begun to affect timelines. External support can be useful before a major development milestone, when manufacturing or analytical activities are becoming more complex, when several external partners are generating information or when internal regulatory resources are temporarily stretched.

Another useful trigger is uncertainty about the current state of the documentation. If teams are repeatedly revisiting the same issues, working from inconsistent source information or discovering missing justification late in the process, a targeted regulatory gap analysis can help clarify where remediation is needed. The role of the CMC advisor can then be to support the CMC-specific actions that follow, rather than duplicating the broader gap-analysis exercise.

Timing also matters after approval. Product and manufacturing changes create new CMC work throughout the lifecycle, and companies need enough lead time to understand what documentation, data and regulatory actions will be required. Bringing external expertise in before deadlines become compressed allows the advisor to understand the background, coordinate contributors and prepare the necessary work in a controlled way. The right moment is therefore the point at which additional expertise, capacity or coordination can make the next milestone easier to execute – not the point at which the team has already run out of time.

How can external CMC support work alongside your internal regulatory team?

External CMC support should strengthen the internal team rather than create a parallel structure. The engagement works best when the external CMC advisor understands who owns the regulatory pathway, who provides technical decisions and where the advisor is expected to take action. This lets the client retain control while adding specialist capacity where it is needed.

For some organisations, the internal point of contact may be a regulatory affairs specialist who coordinates submissions and lifecycle work but needs additional CMC depth. In other cases, a broader regulatory affairs consultant may already support the company, with a dedicated CMC workstream added for a specific product or milestone. Clear responsibilities help avoid duplicated review and unclear ownership.

A good working model also keeps communication efficient. The CMC advisor should know which questions can be resolved directly with technical contributors, which decisions require internal approval and when wider regulatory input is needed. That clarity reduces handovers and smoothly aligns support with the workload, while keeping full ownership of the programme.

Frequently asked questions about working with a CMC advisor

Ready to choose the right CMC support model?

Choosing the right CMC advisor is ultimately about finding a working model that matches the product, the internal team and the milestone ahead. Direct access to experienced expertise, clear ownership of deliverables and the ability to move from advice into execution can make external support far more useful than a purely high-level advisory relationship.

For companies assessing alternatives to large pharma-affiliated cmc advisors, Billev Pharma East offers hands-on CMC and regulatory support that can be tailored to the actual scope of the programme. Our team can support CMC writing, dossier preparation, submissions, lifecycle activities and authority communication while working directly with your internal and external technical stakeholders.

If you need a CMC advisor who can become part of the working team and help turn CMC requirements into completed regulatory work, contact Billev Pharma East to discuss your next development, submission or lifecycle milestone.

Sources: 1 – International Council for Harmonisation (ICH). ICH Q11: Development and Manufacture of Drug Substances, 2 – European Medicines Agency (EMA). ICH M4Q – Common Technical Document for the Registration of Pharmaceuticals for Human Use – Quality, 3 – International Council for Harmonisation (ICH). ICH Q10: Pharmaceutical Quality System, 4 – International Council for Harmonisation (ICH). ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, 5 – European Medicines Agency (EMA). Guideline on the Chemistry of Active Substances.